3 Chronic Therapy Brand Company, Formulations Exporter and Largest Indian Pharma Group Stocks With a Strong Future Roadmap: Eris Lifesciences, Marksans Pharma and Sun Pharma
- October 28, 2026
- Posted by: Neeraj Pandey
- Category: Best Stocks
Eris Lifesciences, Marksans Pharma and Sun Pharma: ROE of 13.7% to 15.9% and FY22 to FY26 revenue CAGR of 11.6% to 22.9%. Prices as of 27 Oct 2026.
Quick Answer
The three chronic brand, export and leader pharma to watch are Eris Lifesciences, Marksans Pharma and Sun Pharma. Their return on equity ranges from 13.7% to 15.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 11.6% to 22.9%. Eris Lifesciences leads on both return on equity at 15.9% and revenue growth at 22.9% a year. Prices are based on the 27 October 2026 close, and this article is educational, not investment advice.
Chronic brand, export and leader pharma offer a focused view of a sector where demand keeps widening. Eris Lifesciences, Marksans Pharma and Sun Pharma cover a chronic therapy brand company, a formulations exporter and the largest Indian pharma group.
This list covers three chronic brand, export and leader pharma with complete current figures: Eris Lifesciences, Marksans Pharma and Sun Pharma. Every figure comes from the latest reported financials and the 27 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Chronic Brand, Export and Leader Pharma?
Chronic brand, export and leader pharma are listed pharmaceutical companies that sell branded formulations in cardiac, diabetes and stomach therapies, make over-the-counter and prescription medicines for export and lead in branded and specialty medicines. Their earnings depend on launches, approvals and demand in many markets.
Chronic Brand, Export and Leader Pharma at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Eris Lifesciences | 1,198.4 | 15,618 | 23.5 | 36.0 | 15.9 | 0.60 |
| Marksans Pharma | 300.1 | 12,994 | 24.9 | 35.7 | 13.8 | 0.11 |
| Sun Pharma | 1,751.2 | 422,283 | 34.9 | 36.2 | 13.7 | 0.06 |
On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing chronic brand, export and leader pharma should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Chronic Brand, Export and Leader Pharma Have a Strong Roadmap in India?
Chronic brand, export and leader pharma have a strong roadmap in India because chronic disease care, rising healthcare spending and wider access to affordable medicines keep widening the market for Indian pharmaceutical firms.
- Chronic care. Long-term therapies support repeat sales.
- Export markets. Formulations reach regulated markets.
- Specialty growth. New brands broaden the product mix.
Why Eris Lifesciences Features Among These Chronic Brand, Export and Leader Pharma
Among the chronic brand, export and leader pharma on this list, Eris Lifesciences is an Indian pharmaceutical company with branded formulations in chronic therapies such as cardiac, diabetes and gastro-intestinal care, along with an injectables business.
In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore. Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%.
Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%. The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P/E of 23.5, below the industry P/E of 36.0.
Roadmap: Its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.
What to watch: Check how smoothly acquired brands are integrated and how the injectables unit scales.
Why Marksans Pharma Features Among These Chronic Brand, Export and Leader Pharma
Among the chronic brand, home remedy and generics shares on this list, Marksans Pharma is a Mumbai-based drug maker that produces over-the-counter and prescription formulations at plants in India and sells them in the United Kingdom, the United States, Australia and other markets.
The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 12,994 crore. The stock trades at a P/E of 24.9, below the industry P/E of 35.7.
Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%. Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%. In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore.
Roadmap: The company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.
What to watch: Track export growth, new product approvals and plant utilisation.
Why Sun Pharma Features Among These Chronic Brand, Export and Leader Pharma
Among the three companies on this list, Sun Pharmaceutical Industries is India’s largest pharmaceutical company by market value, with branded generics in India, generics in the United States and a growing specialty medicines business for skin and eye care.
Revenue rose from Rs 39,730 crore in FY22 to Rs 61,674 crore in FY26, a compound annual growth rate of 11.6%. Net profit grew from Rs 3,406 crore in FY22 to Rs 11,565 crore in FY26, which works out to a compound annual growth rate of 35.7%.
In the June 2026 quarter, revenue grew 11.9% year on year to Rs 16,024 crore, while net profit rose 26.4% to Rs 2,911 crore. The company has a return on equity of 13.7%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 422,283 crore. The stock trades at a P/E of 34.9, below the industry P/E of 36.2.
Roadmap: The company is building its specialty portfolio and widening its range of complex generics, while its domestic branded business leads several prescription segments. A global manufacturing network supports supply across many markets.
What to watch: Track specialty product launches, United States approvals and domestic prescription trends.
Eris Lifesciences vs Marksans Pharma vs Sun Pharma on Key Financials
The table below sets the three chronic brand, export and leader pharma side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Eris Lifesciences | 1,373 | 3,137 | 22.9% | 648 | 20.6% |
| Marksans Pharma | 1,533 | 3,033 | 18.6% | 420 | 13.8% |
| Sun Pharma | 39,730 | 61,674 | 11.6% | 11,565 | 18.8% |
Eris Lifesciences posts the highest return on equity in this group at 15.9%. Sun Pharma has the largest FY26 revenue at Rs 61,674 crore, and Eris Lifesciences shows the fastest revenue growth with a 22.9% compound annual rate. A useful habit with chronic brand, export and leader pharma is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Eris Lifesciences | 776 | 876 | 12.9% |
| Marksans Pharma | 626 | 866 | 38.5% |
| Sun Pharma | 14,316 | 16,024 | 11.9% |
Key Risks to Check Before Investing in Chronic Brand, Export and Leader Pharma
Every theme carries risks that deserve a check before any decision. For these chronic brand, export and leader pharma, the main points are: Long-term chronic brand, home remedy and generics shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Pricing pressure. Generic prices can change by market.
- Currency moves. Export earnings move with the rupee.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter chronic brand, export and leader pharma by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Chronic Brand, Export and Leader Pharma
Chronic brand, export and leader pharma reward patient research into demand, execution and financial strength. Eris Lifesciences, Marksans Pharma and Sun Pharma each have a clear plan to grow. Based on the 27 October 2026 close, Eris Lifesciences trades at Rs 1,198.4, Marksans Pharma at Rs 300.1 and Sun Pharma at Rs 1,751.2. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these chronic brand, export and leader pharma to a watchlist.
Download the Univest iOS App or Univest Android App to track chronic brand, export and leader pharma, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are chronic brand, export and leader pharma?
Ans. Chronic brand, export and leader pharma are listed pharmaceutical companies that sell branded formulations in cardiac, diabetes and stomach therapies, make over-the-counter and prescription medicines for export and lead in branded and specialty medicines. Their earnings depend on launches, approvals and demand in many markets. This list looks at three of them, Eris Lifesciences, Marksans Pharma and Sun Pharma, using reported FY22 to FY26 financials and the 27 October 2026 closing prices.
Which chronic brand, export and leader pharma are covered in this list?
Ans. This list covers Eris Lifesciences, Marksans Pharma and Sun Pharma. Based on the 27 October 2026 close, Eris Lifesciences traded at Rs 1,198.4, Marksans Pharma at Rs 300.1 and Sun Pharma at Rs 1,751.2. Their return on equity ranges from 13.7% to 15.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 11.6% to 22.9%.
Why do chronic brand, export and leader pharma have a strong future roadmap in India?
Ans. Chronic brand, export and leader pharma have a strong roadmap in India because chronic disease care, rising healthcare spending and wider access to affordable medicines keep widening the market for Indian pharmaceutical firms. The main drivers are as follows. Chronic care. Long-term therapies support repeat sales. Export markets. Formulations reach regulated markets. Specialty growth. New brands broaden the product mix. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Eris Lifesciences performed financially?
Ans. Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%. Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%. In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore. The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P/E of 23.5, below the industry P/E of 36.0. Looking ahead, its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.
How has Marksans Pharma performed financially?
Ans. Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%. Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%. In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore. The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 12,994 crore. The stock trades at a P/E of 24.9, below the industry P/E of 35.7. Looking ahead, the company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.
How has Sun Pharma performed financially?
Ans. Revenue rose from Rs 39,730 crore in FY22 to Rs 61,674 crore in FY26, a compound annual growth rate of 11.6%. Net profit grew from Rs 3,406 crore in FY22 to Rs 11,565 crore in FY26, which works out to a compound annual growth rate of 35.7%. In the June 2026 quarter, revenue grew 11.9% year on year to Rs 16,024 crore, while net profit rose 26.4% to Rs 2,911 crore. The company has a return on equity of 13.7%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 422,283 crore. The stock trades at a P/E of 34.9, below the industry P/E of 36.2. Looking ahead, the company is building its specialty portfolio and widening its range of complex generics, while its domestic branded business leads several prescription segments. A global manufacturing network supports supply across many markets.
What risks should investors check before buying chronic brand, export and leader pharma?
Ans. Investors should check a few risks before buying chronic brand, export and leader pharma. Regulatory approvals. Plant inspections and approvals can affect supplies. Pricing pressure. Generic prices can change by market. Currency moves. Export earnings move with the rupee. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of chronic brand, export and leader pharma investment advice?
Ans. No. This article is educational and uses publicly available data as of the 27 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
